If you are one of our partner providers and have not received your login credentials yet, please contact us at help@cancerscanuk.co.uk.
Validated through meticulous clinical studies, the TruCheck test identifies Circulating Tumor Cells (CTCs) and their clusters, which may signify the presence of cancer. When employed in conjunction with guideline recommended screening procedures, TruCheck can enhance the probability of early cancer detection.
TruCheck screens for a signal indicative of various cancer types using just one blood test, many of which do not have recommended screening tests. TruCheck extends beyond routine cancer screenings (breast, lung – for those at risk, colon, cervical, and prostate) to screen for additional cancers, such as stomach and pancreatic.
TruCheck is a screening test and does not diagnose cancer. Diagnostic testing is necessary to confirm cancer. The TruCheck test does not detect a signal for all cancers, and not all cancers can be detected in the blood.
The false positive rate is the percentage of individuals without cancer who get a “Cancer Detected” result.
The TruCheck test has a <1% false positive rate, implying that 1 out of 100 people who do not have cancer will receive a “Cancer Detected” result. This low false positive rate helps limit the possibility of a cancer-free individual receiving a “Cancer Detected” result, thereby minimising unnecessary follow-up diagnostic procedures to confirm the presence of cancer.
The predicted Cancer Signal Source (CSS) assists in determining the next steps for cancer confirmation. With a Cancer Signal Detected result, TruCheck predicts the Cancer Signal Source. This prediction provides insights about the tissue type or organ related to the cancer signal. In patients with a confirmed cancer diagnosis following a TruCheck Cancer Signal Detected result, the test was accurate 88% of the time in predicting the Cancer Signal Source. If the predicted Cancer Signal Source does not result in a cancer diagnosis, it could mean that the cancer could not be detected or is located elsewhere.
These lethal cancers often shed more Circulating Tumor Cells (CTCs) into the bloodstream during early stages, account for two-thirds of cancer fatalities, and are more likely to be identified by the TruCheck test.
The TruCheck test is suggested for use in adults with a higher risk of cancer, typically those aged 50 or above. TruCheck does not detect all types of cancers and should be considered a supplemental tool alongside routine cancer screening tests advised by your healthcare provider. The primary goal of TruCheck is to identify cancer signals and predict their origin within the body. It is not recommended for use in individuals who are pregnant, under the age of 40, or currently undergoing active cancer treatment.
Results must be analysed by a healthcare professional, taking into account the patient’s medical history, clinical signs, and symptoms. A result of “No Cancer Signal Detected” does not definitively exclude the presence of cancer. Likewise, a “Cancer Signal Detected” result necessitates further diagnostic evaluation through established medical procedures (such as imaging) to confirm the presence of cancer.
In cases where further testing does not confirm cancer, this could indicate either the absence of cancer or that the test was unable to detect it, including situations where the cancer is located in a different part of the body. Be aware that false-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) results can occur.
1. Akolkar et al. B15: Circulating tumor cells express tissue specific antigens in multiple cancers. Clin Cancer Res.2020;
26(11_Suppl). DOI: 10.1158/1557-3265.LiqBiop20-B15.
2. Akolkar et al. Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer. Int. J.
Cancer:2019; 146, 3485-3494. DOI: 10.1002/ijc.32815.
3. Gaya A et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol.
2020; 129 (3) 226-238 doi: 10.1002/cncy.22366.
4. Ranade A et al. Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer
Prev Res. 2021;14:11-6 DOI:10.1158/1940-6207.CAPR-20-0322.
5. Crook T et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers
(Basel). 2022 Jul; 14(14): 3341. DOI: 10.3390/cancers14143341.
